Loading clinical trials...
Loading clinical trials...
Exploratory Evaluation of Genetic Polymorphism and Pharmacodynamic Parameters in Samples of Abira-DES Study Subjects (NCT02217566) - Subjects With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol.
The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer after unresponsive use of diethylstilbestrol.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes
São Paulo, Brazil
Start Date
March 19, 2020
Primary Completion Date
November 16, 2020
Completion Date
November 16, 2020
Last Updated
January 3, 2022
42
ACTUAL participants
Serum and plasma samples analysis
OTHER
Lead Sponsor
Janssen-Cilag Farmaceutica Ltda.
NCT06842498
NCT05489211
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07476001